Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fang Lin

Showing results (1451-1460 of 1,484) with videos related to

Pageof 149
Sort By:
Journal of Medicinal Chemistry|February 24, 2012
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)John F Kadow, Yasutsugu Ueda, Nicholas A Meanwell, et al.
Journal of Medicinal Chemistry|June 20, 2018
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug FostemsavirTao Wang, Yasu Ueda, Zhongxing Zhang, et al.
Journal of Virology|March 31, 2006
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry eventsHsu-Tso Ho, Li Fan, Beata Nowicka-Sans, et al.
Journal of Virology|July 29, 2016
The Ubiquitin Ligase Itch and Ubiquitination Regulate BFRF1-Mediated Nuclear Envelope Modification for Epstein-Barr Virus MaturationChung-Pei Lee, Guan-Ting Liu, Hsiu-Ni Kung, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agentsKap-Sun Yeung, Zhilei Qiu, Quifen Xue, et al.
Theranostics|April 16, 2021
c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activationYa-Chu Tang, Jenn-Ren Hsiao, Shih-Sheng Jiang, et al.
Journal of Hepatology|May 22, 2020
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19Yijin Wang, Shuhong Liu, Hongyang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activityNicholas A Meanwell, Owen B Wallace, Henry Wang, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|August 3, 2024
Przewaquinone A inhibits Angiotensin II-induced endothelial diastolic dysfunction activation of AMPKSi Chen, Jun-di Xie, Meng-Ting Xie, et al.
JCI Insight|May 20, 2020
Clinical and pathological investigation of patients with severe COVID-19Shaohua Li, Lina Jiang, Xi Li, et al.
Pageof 149

Showing results (1451-1460 of 1,484) with videos related to

Sort By:
Pageof 149
Journal of Medicinal Chemistry|February 24, 2012
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)John F Kadow, Yasutsugu Ueda, Nicholas A Meanwell, et al.
Journal of Medicinal Chemistry|June 20, 2018
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug FostemsavirTao Wang, Yasu Ueda, Zhongxing Zhang, et al.
Journal of Virology|March 31, 2006
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry eventsHsu-Tso Ho, Li Fan, Beata Nowicka-Sans, et al.
Journal of Virology|July 29, 2016
The Ubiquitin Ligase Itch and Ubiquitination Regulate BFRF1-Mediated Nuclear Envelope Modification for Epstein-Barr Virus MaturationChung-Pei Lee, Guan-Ting Liu, Hsiu-Ni Kung, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agentsKap-Sun Yeung, Zhilei Qiu, Quifen Xue, et al.
Theranostics|April 16, 2021
c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activationYa-Chu Tang, Jenn-Ren Hsiao, Shih-Sheng Jiang, et al.
Journal of Hepatology|May 22, 2020
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19Yijin Wang, Shuhong Liu, Hongyang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activityNicholas A Meanwell, Owen B Wallace, Henry Wang, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|August 3, 2024
Przewaquinone A inhibits Angiotensin II-induced endothelial diastolic dysfunction activation of AMPKSi Chen, Jun-di Xie, Meng-Ting Xie, et al.
JCI Insight|May 20, 2020
Clinical and pathological investigation of patients with severe COVID-19Shaohua Li, Lina Jiang, Xi Li, et al.
Pageof 149